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ABSTRACT
Purpose A pharmacokinetic-pharmacodynamic (PK-PD)
model was developed to describe the time course of brain
concentration and dopamine D2 and serotonin 5-HT2A receptor
occupancy (RO) of the atypical antipsychotic drugs risperi-
done and paliperidone in rats.
Methods A population approach was utilized to describe the
PK-PD of risperidone and paliperidone using plasma and brain
concentrations and D2 and 5-HT2A RO data. A previously
published physiology- and mechanism-based (PBPKPD) model
describing brain concentrations and D2 receptor binding in the
striatum was expanded to include metabolite kinetics, active
efflux from brain, and binding to 5-HT2A receptors in the frontal
cortex.
Results A two-compartment model best fit to the plasma PK
profile of risperidone and paliperidone. The expanded PBPKPD
model described brain concentrations and D2 and 5-HT2A RO
well. Inclusion of binding to 5-HT2A receptors was necessary to
describe observed brain-to-plasma ratios accurately. Simulations
showed that receptor affinity strongly influences brain-to-plasma
ratio pattern.
Conclusion Binding to both D2 and 5-HT2A receptors influen-
ces brain distribution of risperidone and paliperidone. This may
stem from their high affinity for D2 and 5-HT2A receptors.
Receptor affinities and brain-to-plasma ratios may need to be
considered before choosing the best PK-PD model for centrally
active drugs.
KEY WORDS dopamine D2 receptor occupancy .
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ABBREVIATIONS
BBB blood-brain barrier
Bmax receptor density
CL systemic clearance
CLbev passive brain-extravascular clearance
CLbv brain-vascular clearance
CLcor brain-cortex clearance
CLefflux active efflux clearance
CLmet metabolic clearance of RIS to PALI
CLPALI systemic clearance of PALI
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CLRIS systemic clearance of RIS by other
routes than metabolism to PALI
CLstr brain-striatum clearance
CWRES conditional weighted residuals
FIP bioavailability for intraperitoneal
route of administration
FOCE first order conditional estimation method
FrFPM fraction of the absorbed RIS IP dose going directly to
PALI central compartment
FSC bioavailability for subcutaneous route of
administration
fubrain unbound fraction in brain
fuplasma unbound fraction in plasma
GOF goodness-of-fit plots
IIV inter-individual variability
IP intraperitoneal
IV intravenous
Kd receptor dissociation constant
koff receptor dissociation rate constant
kon receptor association rate constant
nM nanomoles/litre
OFV objective function value
PALI paliperidone
P-gp P-glycoprotein
PK-PD pharmacokinetic and pharmacodynamic
Q intercompartmental flow between
central and peripheral compartment
RIS risperidone
RO receptor occupancy
RSE relative Standard Error
SC subcutaneous
Vbev volume of brain-extravascular compartment
Vbv volume of brain-vascular compartment
Vc volume of the central compartment
Vcor volume of frontal cortex compartment
Vp volume of the peripheral compartment
Vstr volume of striatum compartment
INTRODUCTION
Schizophrenia is a chronic psychiatric disorder which affects
almost 1% of the population worldwide (1). It is character-
ized by the presence of positive symptoms (e.g. hallucina-
tions, delusions), negative symptoms (e.g. social withdrawal,
reduced motivation) and cognitive impairments. The ma-
jority of drugs for schizophrenia target psychotic symptoms
as their primary goal (1). It has been hypothesized that
elevated dopamine levels in the striatum lead to psychosis.
This is consistent with the fact that all currently available
antipsychotic drugs act as dopamine D2 receptor antagonists
(with one exception of a partial agonist - aripiprazole) (1).
Usually 65–80% D2 receptor occupancy (RO) is believed to
be necessary for a clinically relevant outcome, but occupan-
cy above 80% leads to side effects, i.e. Extra Pyramidal
Symptoms (EPS)(2).
In addition to blocking D2 receptors, newer antipsy-
chotics (so-called second generation or atypical antipsy-
chotics) have a high affinity towards other receptors.
Specifically, many of them show a higher affinity towards
serotonin 5-HT2A receptors than towards D2 receptors. It
has been hypothesized that this higher 5-HT2A/D2 affinity
ratio contributes to the lower incidence of side effects of
atypical antipsychotic drugs: EPS and prolactin elevation
(3). Binding to 5-HT2A receptors could theoretically also
lead to improved efficacy towards negative symptoms in
schizophrenia (4). 5-HT2A antagonism may confer atypical-
ity on antipsychotic drugs with relatively weaker D2 antag-
onism (or partial D2 agonism) because of the ability of 5-
HT2A receptors to modulate the activity of dopaminergic
neurons differentially in different regions of the brain (5).
Predicting human receptor occupancy in a quantitative
manner based on animal studies is one of the challenges in
the drug discovery and development process. Pharmacoki-
netic and pharmacodynamic (PK-PD) modeling tools are
extensively used to describe drug distribution and effect (6).
Recently utilization of mechanistic factors in the PK-PD
modeling has been strongly advocated (7). Inclusion of
mechanistic factors like biophase distribution and receptor
association and dissociation kinetics allows for a better un-
derstanding of processes leading to the observed data (8), as
well as distinguishing between system- and drug-specific
parameters and extrapolation of drug effects from rat to
human (7).
The aim of this study was to develop a population PK-
PD model describing D2 RO for the atypical antipsychotics
risperidone and paliperidone in rats. As a starting point we
used a hybrid physiologically-based PK-PD model which
has recently been published for the atypical antipsychotic
drug olanzapine in rats (9). This model describes the plasma
pharmacokinetics using conventional compartmental analy-
sis techniques while processes in the brain are described in a
more physiological manner, taking into account the distri-
bution of a drug in the brain and association and dissocia-
tion kinetics at the D2 receptors. Here, we apply this model
to other antipsychotics: risperidone and 9-hydroxy-
risperidone (paliperidone). Both drugs are atypical antipsy-
chotics with high affinity for D2 and 5-HT2A receptors.
Risperidone is metabolized to paliperidone and both drugs
show similar binding properties and clinical effect profiles.
Therefore, to properly describe the RO of risperidone and
eventually its clinical effects it is necessary to take into
account the formation of paliperidone, its distribution to
the brain and its binding to receptors. Therefore, we ex-
tended the previously published model to incorporate me-
tabolite formation, its brain kinetics and its receptor binding
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parameters. Also, since both risperidone and paliperidone
are known P-glycoprotein (P-gp) substrates (10) we included
an active efflux process at the blood-brain- barrier. We also
investigated whether binding to 5-HT2A receptors influ-
enced the PK and PD of both drugs.
METHODS
Data
This work was performed within the framework of the
Dutch Top Institute Pharma project: Mechanism-based
population PK–PD modeling (http://www.tipharma.com).
This modeling platform involves leading global pharma-
ceutical companies and academic institutions from The
Netherlands. Data used for the modeling were generated
previously by the pharmaceutical companies: Janssen Re-
search and Development (Belgium), Merck Sharp &
Dohme Limited (The Netherlands) and Pfizer Global
Research and Development (USA) and were anonimized
before releasing to the modelers. Results from a number
of studies were used including dose-response and time
course studies. Male SpragueDawley orWistar rats were used
for the experiments. Risperidone (RIS) was administrated
intravenously (IV), intraperitoneally (IP) or subcutaneously
(SC) in a wide range of single doses (0.01 to 40 mg/kg). In
most experiments, RIS plasma and brain concentrations and
its RO (either D2 or 5-HT2A) were measured in one animal at
one time point (since animals have to be euthanized for brain
concentration and RO measurements). In a few studies
paliperidone (PALI) concentrations were measured after
RIS or PALI administration. An overview of the studies
utilized is given in Table I. For RO studies either the
striatum or the frontal cortex was removed for the measure-
ment of D2 or 5-HT2A receptor occupancy, respectively. The
rest of the brain was homogenized and drug concentration
was measured. An in vivo or ex vivomethod was used for both
5-HT2A and D2 RO measurements. [
3H]raclopride was
used as a radioligand for D2 RO studies and [
3H]
M100907 for 5-HT2A RO studies. The experimental
procedures for the plasma sample collection, brain dissection,
tissue homogenization and RO measurements were similar
across the different study sites and these procedures were
based on published reports (11,12).
Model Development
We used a population approach to describe the pharmaco-
kinetics and pharmacodynamics (receptor binding) of RIS
and PALI and to obtain population parameter estimates
together with the inter-individual variability. Modeling was
done using the non-linear mixed effects modeling software
NONMEM (version VII level 2) (13). ADVAN 13 subrou-
tine was used to allow explicit writing of differential equa-
tions describing receptor dynamics (Appendix). Log-
Table I Overview of Available Data Used in the PK-PD Analysis
Study # # of rats drug1 ROA2 dose [mg/kg] time points [h] observation type RO method3
1 3 RIS IV 2.5 0.12, 0.33, 1, 2, 4, 8 PC-R NA
2 4 RIS IV 2 0.12, 0.33, 1, 2, 4 PC-R NA
3a 23 PALI SC 5 0.25, 0.5, 1, 2, 4, 8 PC-P, StrC-P, CorC-P NA
3b 23 RIS SC 5 0.25, 0.5, 1, 2, 4, 8 PC-R, PC-P, StrC-R, StrC-P,
CorC-R, CorC-P
NA
4 42 RIS IP 0.3, 3 0.25, 0.5, 1, 1.5, 2, 4, 7 PC-R, PC-P, BC-R, BC-P NA
5 20 RIS IP 1 0.25, 0.5, 1, 1.5, 2 PC-R, BC-R, RO-D2 in vivo
6 23 RIS IP 0.01, 0.03, 0.1, 0.3, 1, 3 1 PC-R, BC-R, RO-D2 in vivo
7 36 RIS SC 0.16, 10 0.5, 1, 2, 4, 8, 24 PC-R, BC-R, RO-D2 ex vivo
8a 12 PALI SC 0.16, 0.63, 2.5, 10 1 RO-D2 in vivo
8b 18 RIS SC 0.04, 0.16, 0.63, 2.5, 10, 40 1 RO-D2 in vivo
9 19 RIS IP 0.01, 0.03, 0.01, 0.3, 1 1 PC-R, BC-R, RO-5HT2A in vivo
10 20 RIS IP 0.1 0.25, 0.5, 1, 1.5, 2 PC-R, BC-R, RO-5HT2A in vivo
11 24 RIS IP 0.01, 0.03, 0.01, 0.3, 1, 3 1 PC-R, RO-5HT2A ex vivo
12 15 RIS IP 0.1, 0.3, 0.8, 1 1 PC-R, RO-5HT2A in vivo
RIS risperidone, PALI paliperidone, IV intravascular, IP intraperitoneal, SC subcutaneous, PC-R RIS plasma concentration, PC-P PALI plasma concentration,
BC brain concentration, StrC striatum concentration, CorC cortex concentration, RO receptor occupancy, NA not applicable
1 drug administered
2 route of administration
3method used for RO measurement
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transformed plasma and brain drug concentrations were
used for the data analysis, and concentrations below the
limit of quantification were excluded from this analysis.
Inter-individual variability (IIV) on each parameter was
modeled assuming a log-normal distribution. Additive, pro-
portional and combined residual error models were tested.
A number of structurally different PK and PD models
have been evaluated (see below). Model selection was based
on the likelihood ratio test, parameter estimates and their
relative standard errors, residual error values and goodness-
of-fit plots. An additional structural parameter or inter-
individual variability was included in the model, if the
resulting change in objective function value (ΔOFV) was
>6.64 (p<0.01 assuming χ2 distribution). The following
goodness-of-fit plots were inspected visually in order to
assess the fit of the model to the data: observations versus
population and individual predictions, individual weighted
residuals versus individual predictions and conditional
weighted residuals (CWRES) versus time.
During the analysis, Pirana software (14) was used for
NONMEM run management and Xpose package in R
(15,16) for making diagnostic plots.
General Model Structure and Modeling Approach
We did a sequential analysis where we first described
the plasma PK of RIS and PALI in a conventional
compartmental way. We assumed that this analysis pro-
vides an adequate description of concentration in
plasma, which in turn is the driving concentration for
the brain distribution and receptor binding model.
Therefore, it is appropriate to fix plasma parameters
while simultaneously estimating brain distribution and
receptor binding parameters from brain concentration
and receptor occupancy data. This has been done in
the second part of the analysis.
Plasma PK Model
One- and two-compartment models for both RIS and PALI
were tested. For SC and IP administration different absorp-
tion models were tested: zero-order and first-order absorp-
tion in combination with a lag time. For IP dosing of RIS we
checked models with and without first pass metabolism by
assuming that part of the administered RIS dose is con-
verted to PALI before reaching the systemic circulation.
Bioavailability for IP and SC doses were estimated relative
to IV dosing. Since there were no data after IV administra-
tion of PALI, we assumed that RIS and PALI have the same
bioavailability for the SC route of administration. This
allows estimating the volume of distribution and other ab-
sorption parameters of PALI. To account for metabolite
formation we divided the elimination clearance for RIS into
two clearances: metabolic clearance to PALI (CLmet) and
clearance by other routes of elimination (CLRIS) (Fig. 1).
First-order conditional estimation method (FOCE) was used
to obtain PK parameter estimates.
Fig. 1 A schematic representation of the plasma PK model. Plasma PK of both RIS and PALI follows a two-compartment model. IV and IP dosing goes
directly to the central compartment. A fraction of the absorbed dose for IP RIS route of administration goes directly to the RIS central compartment and a
fraction of the absorbed dose goes to the PALI central compartment (FrFPM) representing first pass metabolism. Absorption after SC dosing is described by
consecutive zero- and first order processes for both RIS and PALI. DRSC is the duration of the zero-order process after SC dosing. Total elimination
clearance of RIS is divided into metabolic clearance (CLmet) and the clearance by other routes of elimination (CLRIS).
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PK-PD Modeling
After finding the appropriate plasma PK model, population
parameters for plasma (mean and inter-individual variability)
were fixed after which brain concentrations and RO were
fitted simultaneously. Initially only D2 RO was taken into
account as D2 binding is assumed to be crucial for the drug’s
antipsychotic action (2). We started with the previously pub-
lished hybrid physiologically-based PK-PDmodel (9), but also
checked simplifications of this model, i.e. binding not affecting
brain kinetics (simplified model from (9)) and reduction in the
number of brain compartments by merging intra- and extra-
vascular compartments together or assuming only one com-
partment for drug not bound to receptors in the brain.
The hybrid physiology-based PK-PD model consists of
four compartments in brain: vascular, extra-vascular, striatum
free and striatum bound compartment (Fig. 2). Volumes of
these compartments were fixed to physiological values:
0.00024, 0.00656, 0.0002 L/kg for vascular, total extra-
vascular and striatum, respectively (17,18). Clearance
between plasma and vascular compartment (CLbv) was
assumed to be equal to cerebral blood flow in rats, which
is 0.312 L/h/kg (17), for both RIS and PALI. In the
model, transport of RIS and PALI between the vascular
and extra-vascular compartment across the blood-brain
barrier (BBB) was governed by two processes: passive
diffusion and active efflux. Separate values of passive
clearance (CLbev) and active efflux clearance (CLefflux)
were estimated for RIS and PALI when possible. We checked
whether linear or saturable efflux processes described the data
best. Only unbound drug could cross the brain-blood barrier
(BBB). Plasma protein binding is constant over wide range of
concentrations in humans (19). We assumed that the same is
true for rats and plasma and brain fraction unbound were
fixed to literature values: fuplasma-RIS00.0798, fubrain-RIS0
0.0699, fuplasma-PALI00.129, fubrain-PALI00.0755 (20).
We assumed fast equilibration between the extra-
vascular and striatum free compartments. This was achieved
Fig. 2 (a) A schematic representation of the PK-PD model. The plasma PK has been omitted (see Fig. 1) and brain kinetics and receptor binding have been
presented here for one drug only because of the complexity of the model. The same model structure applies for RIS and PALI. (b) Representation of the
competitive binding to the same receptors by RIS and PALI. Measured RO is the sum of occupancies obtained by both drugs. Here only binding to D2
receptors is shown. The same principle applies for 5-HT2A receptors. [D2] - concentration of free D2 receptors, [R] – unbound concentration of RIS, [D2R]
- concentration of D2 receptor complex with RIS, [P] – unbound concentration of PALI, [D2P] - concentration of D2 receptor complex with PALI. D2
receptor occupancy (RO) is the sum of RO exerted by both drugs.
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by fixing the corresponding clearance (CLstr) to a high value
(500 L/h/kg). In striatum, RIS and PALI reversibly bind to
D2 receptors. Binding to receptors was described using kon
as the receptor association rate constant (nM−1 h−1), koff as
the receptor dissociation rate constant (h−1), and Bmax as the
maximum binding capacity of these drugs to the receptor.
Including explicit binding kinetics is justified because of the
hysteresis observed between D2 (or 5-HT2A) receptor occu-
pancy and brain concentration when excluding striatum or
frontal cortex (from D2 and 5-HT2A occupancy studies,
respectively; data not shown). RIS and PALI compete for
the same receptors and hence the measured RO is the sum
of occupancies obtained by both drugs.
Both RIS and PALI have a strong affinity towards 5-
HT2A receptors. Therefore, we decided to evaluate also an
extended model in which we included binding to these
receptors in the frontal cortex, where the density of 5-
HT2A receptors is the highest (21). To that end, we included
two additional compartments: cortex free and cortex bound.
We fixed the volume of frontal cortex to 0.0035 L/kg (22).
As for striatum, we assumed fast equilibration between brain
extra-vascular and cortex free compartments. Binding to 5-
HT2A receptors was described using kon, koff and Bmax
values specific for these receptors. Kd (dissociation rate
constant) and koff were estimated from the model and kon
was calculated as koff/Kd. We checked whether we could
estimate different binding constants for data obtained from
in vivo and ex vivo binding experiments.
First-order conditional estimation method (FOCE) was
used to fit the models.
Model Evaluation
For the plasma PK model a bootstrap analysis was done to
determine the precision of the parameter estimates. In the
bootstrap technique, bootstrap replicates are generated by
randomly sampling individuals from the original dataset
with replacement. 1000 samples were used and they were
stratified by study. Parameter estimates for each of the re-
sampled datasets were obtained by fitting the final plasma
PK model using NONMEM. Median, 5-th and 95-th per-
centiles were calculated for all the parameters and medians
of bootstrap estimates were compared with parameter val-
ues obtained from the original dataset.
Additionally, since the original dataset is rather hetero-
geneous and bootstrapping may lead to biased results, we
also did log-likelihood profiling (LLP). In this method each
parameter is in turn fixed to lower or higher values than the
one estimated by the model and the reduced model is fit to
the data. Obtained OFV is compared with the OFV of the
original model. The 90% confidence interval (CI) of a
parameter is calculated by finding the value of the param-
eter at which the difference in OFV is 3.84 (p00.05
assuming χ2 distribution). Bootstrap analysis and log-
likelihood profiling were done with the help of the software
package Perl Speaks NONMEM (PsN) (23).
Due to the great heterogeneity of the dataset and very
long run times we did not perform a bootstrap analysis for
the PD model. However, we did the log-likelihood profiling
to find 90% CIs of the parameter values.
In order to check the predictive performance of the model
we simulated 1000 datasets from the final PK-PD model.
Then we graphically compared the observed plasma and
brain concentrations and D2 and 5-HT2A RO with median
and 90% prediction intervals calculated from the simulated
data for each dose and route of administration separately.
Brain-To-Plasma Ratios
We simulated brain and plasma concentrations based on
population parameter estimates (without inter-individual
and residual variability) for doses and time points
corresponding to the ones seen in the data set. For each
simulated time point we calculated brain-to-plasma ratios
and compared them graphically with the observed brain-to-
plasma ratios, plotting only brain-to-plasma values if both
plasma and brain concentrations were above the level of
quantification. To check the influence of different parameters,
we also simulated the brain-to-plasma ratio pattern in the
absence of active efflux and with a 10 times higher value of
brain clearances and of increases or decreases of the receptor
association and dissociation constants kon and koff. To that
end, we either fixed CLefflux to zero or used CLbev and CLefflux
10 times higher than estimated from the model, or kon/koff
values 10 times lower or higher than estimated by the model.
All other parameter values were the same as estimated by the
model. We used R software for the simulations.
RESULTS
Plasma PK
Plasma PK was best described by a two-compartment model
for both RIS and PALI (Fig. 1). For the SC route of admin-
istration consecutive zero- and first-order absorption de-
scribed the data best. For the IP route absorption
parameters could not be estimated and it was assumed that
dosing was directly to the central compartment. However,
including first pass metabolism where a fraction of the RIS
dose goes directly to the PALI central compartment improved
the fit of the model. Parameter estimates of the final model are
given in Table II. In the final model six inter-individual
variability parameters (for FIP, KaSC-RIS, KaSC-PALI, DRSC-RIS,
CLRIS, CLPALI) were retained.
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Parameters for the rate of zero-order absorption and
volume of distribution and inter-compartmental clearance
for PALI could not be estimated precisely (Table II). How-
ever, we decided to keep them in the model since removing
them led to a significantly worse fit and it was important to
describe the plasma PK as precisely as possible for the
description of brain kinetics and receptor binding.
Goodness-of-fit plots did not show any systematic devia-
tion between observations and population and individual
predictions nor any trends in conditional weighted residuals
versus time, which demonstrates that this model adequately
describes the plasma PK of RIS and PALI (Fig. 3).
PK-PD
The previously published hybrid physiology-based PK-PD
model (9) fitted the data best after adjusting for binding to 5-
HT2A receptors (Fig. 2). A model with only D2 receptor
binding (9) led to high residual error (>60%) for brain
concentration. Using a combined error model reduced the
proportional error to some extent. However, this model did
not explain the observed brain-to-plasma ratio adequately
(Fig. 6a–b). These problems were overcome when the model
was extended to include 5-HT2A receptor binding in frontal
cortex.
Our data did not allow us to estimate reliably all brain
clearance parameters (CLbev-RIS, CLefflux-RIS, CLbev-PALI,
CLefflux-PALI). Change in parameter values within relatively
wide range did not lead to changes in model fit. Therefore, we
assumed that CLbev or CLefflux is the same for RIS and PALI.
Assuming a single CLefflux parameter led to termination prob-
lems. However, the model with a single CLbev value had an
OFV only slightly lower (<0.5) than the model with four
clearance parameters and RSE values obtained from the
covariance step were acceptable. Therefore, in the final model
CLbev was assumed to be the same for RIS and PALI.
Table II Parameter Estimates of the Plasma PK Model from the Original Dataset and from 1,000 Bootstrap Replicates
Parameter Parameter estimate (% RSE) Bootstrap median 5th-95th percentile
from bootstrap
90% CI obtained from
log-likelihood profiling
FIP-RIS 0.412 (12) 0.413 0.314–0.540 0.321–0.530
FSC 0.816 (9) 0.810 0.654–1.03 0.672–0.987
FrFPM 0.268 (12) 0.271 0.213–0.337 0.209–0.332
KaSC-RIS (1/h) 2.84 (20) 2.90 2.25–4.07 2.13–4.16
KaSC-PALI (1/h) 1.31 (22) 1.31 1.00–1.77 0.969–1.84
DRSC-RIS (h) 0.161 (55) 0.170 0.0157–0.313 0.0490–0.283
DRSC-PALI (h) 0.162 (54) 0.167 0.0848–0.261 0.0276–0.320
Vc-RIS (L/kg) 1.29 (6) 1.28 1.07–1.56 1.11–1.49
CLRIS (L/h/kg) 1.62 (9) 1.62 1.29–2.07 1.34–1.95
CLmet (L/h/kg) 0.775 (11) 0.757 0.591–0.974 0.623–0.961
Vp-RIS (L/kg) 0.169 (16) 0.168 0.128–0.223 0.131–0.220
QRIS (L/h/kg) 0.0882 (25) 0.0891 0.0529–0.137 0.0601–0.132
Vc-PALI (L/kg) 1.27 (15) 1.21 0.0647–1.64 0.0087–1.66
CLPALI (L/h/kg) 1.06 (10) 1.04 0.768–1.36 0.847–1.32
Vp-PALI (L/kg) 0.251 (54) 0.281 0.119–2.11 0.0767–75.5
QPALI (L/h/kg) 0.269 (128) 0.245 0.0428–23.4 0.0294–48.3
Inter-individual variability
IIV-FIP (%CV) 80.6 (7.7) 80.4 70.8–89.7 70.0–92.9
IIV-KaSC-RIS (%CV) 46.4 (52.3) 47.9 29.5–70.5 27.1–84.3
IIV-KaSC-PALI (%CV) 34.4 (30.2) 33.0 11.12–50.6 17.0–58.7
IIV-DRSC-RIS (%CV) 91.2 (80.6) 84.2 0.912–287 17.3–211
IIV-CLRIS (%CV) 30.5 (13.3) 29.7 16.3–38.2 23.2–39.0
IIV-CLPALI (%CV) 16.2 (32.8) 16.0 10.4–22.6 10.9–24.5
Proportional residual error
Risperidone 0.233 (16.5) 0.220 0.174–0.279 0.192–0.288
Paliperidone 0.186 (14.2) 0.171 0.131–0.214 0.147–0.238
% RSE - Relative Standard Error as calculated by NONMEM covariance step
Inter-individual variability is expressed as percent coefficient of variation
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Different Kd and koff values for D2 and 5-HT2A were
estimated by the model. However, we were not able to
estimate different Kd and koff values for RIS and PALI,
therefore we assumed that Kd and koff values are the same
for RIS and PALI, which is consistent with literature in vitro
values (24). Similarly, we also had to assume that the bind-
ing rate constants for both in vivo and ex vivo binding RO
measurements were the same. Describing active efflux from
brain as a saturable process did not improve the fit therefore
in the final model the active efflux was assumed to be linear.
Due to the complexity of the model we were not able to
estimate IIV variability for the brain PK-PD model param-
eters. Therefore, we fixed the IIV parameters to zero. Final
parameter estimates of the model are given in Table III.
Goodness-of-fit plots did not show any systematic deviation
between observations and population and individual predic-
tions nor trends in CWRES versus time, which demonstrates
that this model adequately describes the brain concentrations
of RIS and PALI and their D2 RO (Fig. 3). Some time course
pattern can be seen in the plot of CWRES versus time for 5-
HT2A RO, but CWRES values are relatively low.
Model Evaluation
Median bootstrap parameter estimates of the PK model
were in good agreement with model estimated population
values (Table II). 90% confidence intervals were large for
some parameters, especially related to absorption and for
the PALI peripheral compartment.
Results of log-likelihood profiling for brain parame-
ters show that most parameters are estimated precisely
with exception of the brain clearance parameters
(Table III). Further inspection of results showed that
the values of clearance parameters (CLbev, CLefflux-RIS
and CLefflux-PALI) did not influence model fit and other
parameter estimates much. The upper limits of CI for
these parameters could not be found, showing that the
transport is fast and equilibration between brain and
plasma is not much affected by the exact values of
clearances. Moreover, close inspection of the results
show that relative value of active efflux clearance to
passive clearance seems to be very constant. For all the
values of CLbev, CLefflux-RIS and CLefflux-PALI inspected
by LLP, the ratio of CLefflux-RIS to CLbev was in range of
4.57-4.87 while ratio of CLefflux-PALI to CLbev was in
range of 21.1-22.2.
Some of the predictive check results are depicted
in Fig. 4. We present the result for the IP route of
Fig. 3 Goodness-of-fit plots of the PK-PD model. Presented are scatter
plots of plasma and brain concentrations and D2 and 5-HT2A RO versus
population predictions and conditional weighted residuals (CWRES)
versus time.
R
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administration for doses of 0.1 and 1 mg/kg since for
these doses there were time course data available for 5-
HT2A and D2 RO and they had more data points than
other doses. Practically all observations fall within the
range of the 5-th and 95-th percentile. Median time
course of D2 RO is predicted well. For 5-HT2A, RO
seemed to be underestimated for later time points. Pre-
diction intervals are very wide since the residual error
in our model is also relatively big. However, it should
be noted that the variability of the data is also large
(see for example 5-HT2A RO at 1 h).
Inspection of the model-predicted plasma and brain
concentrations for the cases where observations were
reported to be below the level of quantification (LOQ),
shows that exclusion of the observations below LOQ
from the analysis did not lead to a significant bias. For
the studies where LOQ was known, only around 15% of
observations were above LOQ and in less than 5% of the
cases in total predicted concentrations were outside the
confidence intervals based on the residual standard error.
For the studies where LOQ was not known the predicted
concentrations were also low.
Brain-To-Plasma Ratios
The observed brain-to-plasma ratios were higher at lower
plasma concentrations and even out as plasma (or brain)
concentration increases, both for RIS and PALI (Fig. 5).
Even after multiplication of the brain-to-plasma ratio by
fubrain/fuplasma00.876 and obtaining “free brain-to-plasma
ratio”, the brain-to-plasma ratio at higher concentrations is
lower than one due to active efflux from the brain. This
brain-to-plasma ratio pattern was seen for both the total
brain concentration and the concentration measured in
brain excluding striatum (from the studies where D2 RO
was measured) or excluding frontal cortex (from studies
where 5-HT2A RO was measured). A model with only D2
receptor binding in striatum did not predict higher brain-to-
plasma ratios for lower concentrations (Fig. 6a–b). Including
binding to 5-HT2A receptors in the model predicted brain-
to-plasma ratios well (Fig. 6a–c) over the entire concentra-
tion range.
Fixing CLefflux to zero led to an increase of brain-to-
plasma ratios, but the general pattern stayed the same
(Fig. 6d). Increasing CLbev and CLefflux had virtually no
effect on the brain-to-plasma ratios (not shown). If koff
and kon values for both D2 and 5-HT2A receptors were
10 times higher (implying no change in Kd) then brain-
to-plasma ratios at lower concentrations were slightly
lower and at higher concentrations they were the same
as in the original model (Fig. 6e). The same effect was
visible with and without efflux. Increasing Kd by increas-
ing koff leads to an almost constant brain-to-plasma ratio
(Fig. 6f). Increasing Kd by decreasing kon had a similar
effect, but less pronounced (data not shown). If we in-
creased koff for D2 receptors only, then brain-to-plasma
ratios became constant only for brain concentrations
excluding cortex (brain concentration measured in 5-
HT2A RO studies; data not shown). If we increased koff
only for 5-HT2A receptors then brain-to-plasma ratios
became constant only for brain concentrations excluding
striatum (brain concentration measured in D2 RO studies;
data not shown).
DISCUSSION
In this paper we present an extension of the previously
published PK-PD model for olanzapine (9) to two other
antipsychotic drugs: risperidone and paliperidone. This
model describes the time course of D2 receptor occupancy
after administration of the antipsychotics and takes brain
distribution into account. Here, we expand the model by
taking into account metabolite formation and its receptor
binding, active efflux from the brain and binding to 5-HT2A
receptors.
Table III Parameter Estimates of the PK-PD Model and Their Relative
Standard Error
Parameter Parameter
estimate
% RSE 90% CI obtained from
log-likelihood profiling
CLbev-RIS (L/h/kg) 2.13 29 0.333–>1000
c
CLbev-PALI
a(L/h/kg) 2.13 29 0.333–>1000c
CLefflux-RIS (L/h/kg) 9.97 28 1.49–>1000
c
CLefflux-PALI (L/h/kg) 47.0 28 7.24–>1000
c
KdD2 (nM) 0.463 14 0.336–0.628
koffD2 (1/h) 0.671 19 0.427–1.03
konD2
b (1/nM/h) 1.45 – –
Bmax-D2 (nM) 245 15 194–305
Kd5-HT2A (nM) 0.219 15 0.134–0.313
koff5-HT2A (1/h) 0.525 25 0.257–0.970
kon5-HT2A
b (1/nM/h) 2.40 – –
Bmax-5-HT2A (nM) 46.5 11 37.3–58.9
Residual error
proportional BC RIS 0.362 7 0.315–0.419
proportional BC PALI 0.424 18 0.351–0.519
additive % D2 RO 17.7 8 15.1–20.7
additive % 5-HT2A RO 18.2 7 1.49–22.4
% RSE - percent Relative Standard Error as calculated by NONMEM
covariance step
BC brain concentration
a assumed to be the same as CLbev-RIS
b calculated as kon0koff/Kd
c OFV does not change with increasing parameter value
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Some antipsychotic drugs (such as risperidone and aripi-
prazole) have active metabolites. The active metabolite of
risperidone, paliperidone, achieves high concentrations in
plasma and brain (25,26). It also shows potent binding to D2
and 5-HT2A receptors and is by itself a potent antipsychotic
drug (27,28). Therefore, to describe receptor occupancy of a
parent drug in a mechanistic way, it is necessary to take into
account formation, brain kinetics and receptor binding of
the metabolite.
It has been shown in in vitro studies and studies with
knockout mice, that both risperidone and paliperidone are
P-gp substrates (10). Inclusion of active efflux at the BBB in
the model was indeed necessary to describe the data prop-
erly. Relative values of model predicted parameters for
active efflux at the BBB for both drugs are in line with
previous experimental studies. Most of the studies with
mdr1a knockout mice (10,29) show that the difference in
brain-to-plasma ratios between the knockout and the wild-
type mice is considerably larger for paliperidone in compar-
ison to risperidone (with one exception where the ratio is
slightly higher for risperidone (30)). Similar results have
been found in in vitro experiments with MDCK cells in an
transwell assay (31) and are in line with our results. It has
been assumed in our model that the active efflux is a linear
process. This seems to be a valid assumption for risperidone
and paliperidone, since modeling the active transport as a
saturable process did not improve the fit. This is in line with
the finding that the highest brain concentrations of risper-
idone and paliperidone seen in our dataset were around
2 μM, while the Km values (concentration of substrate
yielding half maximum activity) for P-gp transport from in
vitro studies range between 5.6 to 26 μM (30,32,33). So
clearly, the concentrations observed in vivo are far below
the saturation levels for risperidone and paliperidone.
Paliperidone is less lipophilic than risperidone, therefore
one would expect that it will diffuse slower through biolog-
ical membranes. However, in vitro essays show that passive
permeability of risperidone and paliperidone are quite sim-
ilar (31). Therefore, assuming the same value for passive
clearance through BBB can be justified. Probably more
data, especially for paliperidone, would be needed to esti-
mate separate parameters of both drugs. However, it should
be noted that it might be difficult to estimate passive and
active clearance parameters reliably. It seems that, at least in
our dataset, brain concentration is only informative about
the ratio of active and passive processes. Extensive
Fig. 4 Predictive check of the PK-PD model. (a–c) Risperidone plasma concentration, risperidone brain concentration after removing striatum and D2 RO
after IP administration of a 1 mg/kg dose of risperidone, respectively. (d–f) Risperidone plasma concentration, risperidone brain concentration after removing
frontal cortex and 5-HT2A RO after IP administration of a 0.1 mg/kg dose of risperidone, respectively. Dots represent the observed data; the dashed line
represents the median of the observed data; the shaded area represents 90% prediction interval based on 1000 simulated datasets; the grey line represents
the median of the simulated data.
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simulation study would be probably necessary to establish
what data is needed in order to be able to estimate precisely
brain clearance parameters.
Another extension of the previous model developed for
olanzapine is the inclusion of binding to 5-HT2A receptors.
We included binding to 5-HT2A receptors when we ob-
served that the model with binding only to D2 receptors in
striatum did not provide a good fit to the data and also after
inspecting observed and model predicted brain-to-plasma
ratio plots (Fig. 5, 6a–c). The brain-to-plasma ratio was not
constant for risperidone, suggesting the influence of specific
binding to receptors on the brain kinetics. Similar plots
made for olanzapine show that the brain-to-plasma ratio is
practically constant and that the brain concentrations of
olanzapine are higher than those for risperidone (data not
shown). This suggests that olanzapine shows a different
pattern of brain kinetics than risperidone and paliperidone.
Therefore, we explored the influence of the different param-
eters on the brain-to-plasma ratio. First, we simulated brain-
to-plasma ratios assuming no active efflux, to see if higher
brain concentrations would lead to more constant brain-to-
plasma ratios. Our simulations show that even without
efflux, the brain-to-plasma ratios were not constant
(Fig. 6d), suggesting that the higher brain-to-plasma ratio
was not related to the active efflux process. Next we inves-
tigated whether the pattern could be explained by the dis-
equilibrium between plasma and brain caused by slow
transport between the two. However, increasing brain clear-
ance had virtually no effect on brain-to-plasma ratios. We
also looked at the influence of receptor binding parameters
on the brain-to-plasma ratios. Therefore, we simulated the
influence of increasing values for both koff and kon ten-fold,
reflecting a more rapid equilibration of receptor binding,
without changing the receptor affinity Kd. This resulted in
slightly lower brain-to-plasma ratios at the lowest concen-
trations (Fig. 6e). This suggests that the increased brain-to-
plasma ratio may be only partly explained by disequilibrium
between unbound and bound drug. Finally, an increase of
the Kd values by increasing koff or decreasing kon ten-fold
led to more constant brain-to-plasma ratios (Fig. 6f). A
higher Kd implies that receptor occupancy is lower at the
same unbound brain concentration, and therefore the con-
tribution of the bound drug to the total brain concentration
is less pronounced, resulting in a lower brain-to-plasma
ratio.
Olanzapine has lower binding affinity for D2 and 5-HT2A
receptors than risperidone and paliperidone (9,34). Accord-
ing to our model, brain-to-plasma ratios are constant under
these conditions. The lower D2 binding affinity of olanza-
pine as compared with risperidone may explain why for
olanzapine a simpler model with only binding to D2 recep-
tor and binding not affecting brain kinetics could explain the
data well (9). Risperidone and paliperidone have relatively
low values of the dissociation constant for 5-HT2A receptors
Fig. 5 Brain-to-plasma ratios
against plasma concentrations.
(a) Data from studies where
total brain concentration was
measured; circles - RIS,
triangles -PALI. (b) Data from
D2 RO studies where
brain concentration was
measured after removing
striatum. (c) Data from
5-HT2A RO studies where
brain concentration was
measured after removing
frontal cortex. For b and c
only RIS data was available and
different symbols represent
different studies.
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compared to other antipsychotics (34,35), so one would
expect that a simpler model (where binding to 5-HT2A
receptors does not affect brain distribution) could be appro-
priate for these drugs. Even in cases where kon and koff
values are unknown, plotting brain-to-plasma ratios against
plasma concentrations would indicate whether a simpler
model would be appropriate.
In the model for olanzapine, the receptor density (Bmax)
did not influence the model fit and could be removed from
the model (9). For risperidone and paliperidone, receptor
binding influenced brain kinetics, therefore receptor density
was an important parameter. This was demonstrated by the
precise estimate of Bmax for both D2 and 5-HT2A receptors
(Table III). Bmax values estimated by the model were 245
nM and 47.0 nM for D2 receptors in striatum and 5-HT2A
receptors in frontal cortex, respectively. This 5-HT2A recep-
tor density is in line with the values of 25–60 nM estimated
from in vitro studies (36–39) (assuming 10% protein content
(40)). Average D2 receptor density from in vitro studies is
48 nM (40) with a highest estimated value of 75 nM (41).
This is approximately 3 to 5 times lower than the value
estimated by the model. However, some discrepancy is not
surprising since in our model Bmax represents the theoretical
receptor density, while in in vitro assays it represents the
density of receptors available for the radioligand used. Fix-
ing Bmax to values different than the ones estimated by the
model worsened the model fit (results not shown). Simula-
tions showed that changing Bmax values lead to considerable
changes in brain concentration and receptor occupancy
(data not shown).
To our knowledge, no values are published for in vivo or in
vitro association and dissociation constants for D2 or 5-HT2A
receptors in rats for risperidone and paliperidone. In vitro
binding constant (Ki) values (which can approximate Kd
values) for D2 binding found in literature are usually around
2 to 3 nM (34,42–44), however a value of 0.44 for risper-
idone has also been reported (45). For 5-HT2A binding in
vitro Ki values of 0.12–0.39 and 0.25 nM for risperidone and
paliperidone, respectively, have been reported (34,42,43,45).
Therefore, the in vivo values obtained in our model are within
the range of in vitro values in rat tissues for 5-HT2A binding
and somehow on the lower end of the in vitro range for D2
binding. Difference between values obtained in vivo and in vitro
may be caused by different radioligands used in in vitro and in
vivo studies. It is also conceivable that the receptor-binding
properties of drugs in brain neuronal cells under in vivo
Fig. 6 Observed and simulated brain-to-plasma ratios. Open circles in panels a-c represent observed brain-to-plasma ratios for total brain (a), brain
excluding striatum - from D2 RO studies (b) and brain excluding frontal cortex - from 5-HT2A RO studies (c). In all the panels gray dots represent predictions
of our final model. Black dots represent prediction of the model with only D2 receptor binding (a–b), or prediction of final model but assuming no efflux (d),
kon and koff values 10 times higher (e) or koff values 10 times higher (f) than in the final model. Only total brain-to-plasma ratios are depicted in panels d-f.
Qualitatively similar results were obtained for brain concentrations from D2 and 5-HT2A studies.
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conditions differ significantly from those in brain homoge-
nates and membrane fractions (46).
We assumed the same binding affinities for risperidone
and paliperidone, since our data sets did not allow estima-
tion of separate kon and koff values for risperidone and
paliperidone. More receptor occupancy data for paliperi-
done would be necessary to estimate paliperidone associa-
tion and dissociation rate constants. However, since
published in vitro Ki values in rat brain tissues are similar
for risperidone and paliperidone (34), assuming the same
rate constants for both drugs should not lead to much bias,
especially since the parameters were estimated quite pre-
cisely (RSE between 14 and 25%).
Assuming the same values for binding constants for ris-
peridone and paliperidone may theoretically be one of the
reasons why there are relatively big residual errors for brain
concentrations and receptor occupancy estimated in our
model (Table III). This could also apply to RO measure-
ments obtained from in vivo and ex vivo studies. Trying to
estimate separate binding parameters for in vivo and ex vivo
measurements or excluding the less common ex vivo RO data
from the analysis resulted in problems with model conver-
gence and in less precise parameter estimates. Use of differ-
ent rat strains could also theoretically explain at least a part
of the intra- and inter-individual variability. However, when
we plotted individual post-hoc estimates for different
parameters, we did not see any difference between the
different rat strains or different RO measurement methods.
Considerable residual errors both in PK and PD may
stem partly from differences in experimental procedures
(especially brain dissection) on different occasions and at
the different pharmaceutical companies that provided the
data. Body weight variations could also potentially explain a
part of the observed inter-individual variability, but we had
no information of body weight of the rats allowing us to use
it as a covariate in the model. Residual errors could prob-
ably be reduced if there was an inter-individual variability in
brain PK-PD parameters. However, we were not able to
estimate these variabilities and decided to fix them to zero.
A predictive check of the PK-PD model showed that it
can predict D2 RO reasonably well up to 8 h (Figs. 3e and
5). But the model seems to lead to under-prediction at 24 h
(Fig. 3e). Median 5-HT2A RO also seems to be under-
predicted for later time points (Fig. 4). Only two studies
had a time course of D2 RO and one study a time course
of 5-HT2A RO while most of the studies had only observa-
tions at the 1 h time point. On the one hand, this unbal-
anced dataset could lead to parameter estimates which
explain all data well, but with some model misspecification
for the later time points. On the other hand, with just a few
observations for later time points it is difficult to judge if a
deviation between observation and prediction is not just a
random error. More D2 and 5-HT2A RO time course data
are necessary in order to obtain better description of the full
time course of receptor occupancy by the model.
Our dataset shows that binding to receptors influences
brain concentrations and that D2 binding alone could not
explain the data well. In the model we included binding to
D2 and 5-HT2A receptors (the only available data), but both
risperidone and paliperidone also bind to other receptors. In
vitro data with rat tissue or rat cloned cells show that risperidone
and paliperidone have high affinity (Ki not more than 5 times
higher than Ki for D2 receptors) for α1 and α2 adrenoceptors
and for serotonin 5-HT7 receptors (34,44,45). However, den-
sities of all of these receptors in rat brain are relatively low
(below 100 fmol/mg of protein) (47–50). Therefore, we would
not expect the influence of binding to these receptors on brain
kinetics to be significant. Risperidone and paliperidone bind
also to histamine H1 receptors and other subtypes of dopamine
and serotonin receptors (34,45). However, since Ki values for
these receptors are more than 5 times higher than Ki values for
D2 and 5-HT2A receptors, based on our simulations of brain-
to-plasma ratio we would not expect this binding to affect the
rat brain distribution. Similarly, based on in vitro binding to
human cloned receptors and receptor densities in the human
brain (34,51) binding to other receptors should not strongly
influence brain kinetics in human.
Our model can be utilized for the human prediction of
D2 and 5-HT2A RO. Using the sequential approach, human
plasma PK models can be developed separately in a con-
ventional way and receptor occupancy can be predicted
afterwards. Usage of a physiology-based approach in de-
scribing brain distribution and receptor binding allows uti-
lization of human physiological values, in vitro information
and rat-to-human scaling to predict human receptor occu-
pancy. This translational approach can also be used for
drugs which have an active metabolite or show active efflux
at the brain-blood barrier. Since it is known that D2 RO is
linked with clinical outcome and side effects of antipsy-
chotics (2), but that it is difficult and costly to measure, the
ability to predict human D2 RO based on plasma data can
help with linking different doses of drugs with their clinical
effect. This work is ongoing in our research group.
In conclusion, we have shown that the previously
published hybrid physiologically-based model structure
developed for olanzapine (9) can be utilized to describe the
PK-PD of risperidone and paliperidone in rats. However,
some drug-specific adjustments were necessary. Addition of
active metabolite formation and active efflux was straight-
forward. Additionally, binding to 5-HT2A receptors has been
included in order to describe the brain distribution well. This
may stem from the fact that risperidone and paliperidone
have higher affinity to D2 and 5-HT2A receptors than olanza-
pine. Therefore, receptor affinities and brain-to-plasma ratios
may need to be considered before choosing the best PK-PD
model for centrally active drugs.
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APPENDIX
Differential equations used to describe plasma PK:
d AdepotRIS
 
=dt ¼ DOSESCRIS=DRSCRIS t<DRSC–RISð Þ
 kaSCRIS  AdepotRIS
d AcRISð Þ=dt ¼ kaSCRIS  AdepotRIS þ QRIS=VpRIS
   ApRIS
 QRIS=VcRIS
   AcRIS  CLRIS=VcRISð Þ
 AcRIS  ðCLmet=VcRISÞ  AcRIS
d ApRIS
 
=dt ¼ QPALIRIS=VcRIS
   AcRIS
 QPALIRIS=VpRIS
   ApRIS
d AdepotPALI
 
=dt ¼ DOSESCPALI=DRSCPALI t < DRSC–PALIð Þ
kaSCPALI  AdepotPALI
d AcPALIð Þ=dt ¼ kaSCPALI  AdepotPALIþ QPALI=VpPALI
 ApPALI
 QPALI=VcPALIð Þ  AcPALI  CLPALI=VcPALIð Þ
 AcPALI þ CLmet=VcRISð Þ  AcRIS
d ApPALI
 
=dt ¼ QPALI=VcPALIð Þ  AcPALI
 QPALI=VpPALI
   ApPALI
Differential equations used to describe brain kinetics and
receptor binding:
d AbvRISð Þ=dt ¼ CLbv=VcRISð Þ  AcRIS  CLbv=Vbvð Þ  AbvRIS
 CLbevRIS=Vbvð Þ  f uplasmaRIS  AbvRIS
þ CLbevRIS=Vbevð Þ  f ubrainRIS  AbevRIS
þ CLeffluxRIS=Vbevð Þ  f ubrainRIS  AbevRIS
d AbevRISð Þ=dt ¼ CLbevRIS=Vbvð Þ  f uplasmaRIS  AbvRIS
 CLbevRIS=Vbevð Þ  f ubrainRIS  AbevRIS
 CLeffluxRIS=Vbevð Þ  f ubrainRIS  AbevRIS
 CLstr=Vbevð Þ  f ubrainRIS  AbevRIS
þ CLstr=Vstrð Þ  f ubrainRIS  AstrFRIS
 CLcor=Vbevð Þ  f ubrainRIS  AbevRIS
þ CLcor=Vcorð Þ  f ubrainRIS  AcorFRIS
d AstrFRISð Þ=dt ¼ CLstr=Vbevð Þ  f ubrainRIS  AbevRIS
 CLstr=Vstrð Þ  f ubrainRIS  AstrFRIS
 konD2  f ubrainRIS  AstrFRIS
 ðBmaxD2  CBD2RIS  CBD2PALIÞ
þ kof f D2  AstrBRIS
d AstrBRISð Þ=dt ¼ konD2  f ubrainRIS  AstrFRIS
 ðBmaxD2  CBD2RIS  CBD2PALIÞ
 kof fD2  AstrBRIS
d AcorFRISð Þ=dt ¼ CLcor=Vbevð Þ  f ubrainRIS  AbevRIS
 CLcor=Vcorð Þ  f ubrainRIS  AcorFRIS
 kon5HT2A  f ubrainRIS  AcorFRIS
 ðBmax5HT2A  CB5HT2ARIS
 CB5HT2APALIÞ þ kof f 5HT2A
 AcorBRIS
d AcorBRISð Þ=dt ¼ kon5HT2A  f ubrainRIS  AcorFRIS
 ðBmax5HT2A  CB5HT2ARIS
 CB5HT2APALIÞ  kof f 5HT2A
 AcorBRIS
d AbvPALIð Þ=dt ¼ CLbv=VcPALIð Þ  AcPALI  CLbv=Vbvð Þ
 AbvPALI  CLbevPALI=Vbvð Þ  f uplasmaPALI
 AbvPALI þ CLbevPALI=Vbevð Þ  f ubrainPALI
 AbevPALIþ CLeffluxPALI=Vbevð Þ  f ubrainPALI
 AbevPALI
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d AbevPALIð Þ=dt ¼ CLbevPALI=Vbvð Þ  f uplasmaPALI  AbvPALI
 CLbevPALI=Vbevð Þ  f ubrainPALI  AbevPALI
 ðCLeffluxPALI=VbevÞ  f ubrainPALI  AbevPALI
 CLstr=Vbevð Þ  f ubrainPALI  AbevPALI
þ ðCLstr=VstrÞ  f ubrainPALI  AstrFPALI
 CLcor=Vbevð Þ  f ubrainPALI  AbevPALI
þ CLcor=Vcorð Þ  f ubrainPALI
 AcorFPALI
d AstrFPALIð Þ=dt ¼ CLstr=Vbevð Þ  f ubrainPALI  AbevPALI
 ðCLstr=VstrÞ  f ubrainPALI  AstrFPALI
 konD2  f ubrainPALI  AstrFPALI
 ðBmaxD2  CBD2RIS  CBD2PALIÞ
þ kof fD2  AstrBPALI
d AstrFPALIð Þ=dt ¼ konD2  f ubrainPALI  AstrFPALI
 ðBmaxD2  CBD2RIS  CBD2PALIÞ
 kof f D2  AstrBPALI
d AcorFPALIð Þ=dt ¼ CLcor=Vbevð Þ  f ubrainPALI  AbevPALI
 CLcor=Vcorð Þ  f ubrainPALI  AcorFPALI
 kon5HT2A  f ubrainPALI  AcorFPALI
 ðBmax5HT2A  CB5HT2ARIS
 CB5HT2APALIÞ þ kof f 5HT2A  AcorBPALI
d AcorBPALIð Þ=dt ¼ kon5HT2A  f ubrainPALI  AcorFPALI
 ðBmax5HT2A  CB5HT2ARIS
 CB5HT2APALIÞ  kof f 5HT2A
 AcorBPALI
Where subscripts RIS and PALI denote parameters re-
ferring to risperidone and paliperidone, respectively. Sub-
scripts depot, p, c, bv, bev, strF, strB, corF, corB represent
volumes (V) and amounts (A) in depot (only for SC dosing),
central, peripheral, brain vascular, brain extravascular,
striatum free, striatum bound, frontal cortex free, frontal
cortex bound compartments. DRSC represents duration of
zero-order absorption process for SC dosing. kaSC is the
absorption rate constant for SC dosing. CL, Q, CLbv,
CLstr, CLcor represent clearance in the central, peripheral,
brain vascular, striatum free, cortex free compartments,
respectively. CLmet represent metabolic conversion of RIS to
PALI. CLbev and CLefflux represent passive diffusion and
active efflux through the BBB. Bmax is the receptor density.
CB are concentrations bound to receptor in nM. They are
calculated as follows:
CBD2RIS ¼ 1000  AstrBRIS=Vstr=MWRIS
CBD2PALI ¼ 1000  AstrBPALI=Vstr=MWPALI
CB5HT2ARIS ¼ 1000  AcorBRIS=Vcor=MWRIS
CB5HT2APALI ¼ 1000  AcorBPALI=Vcor=MWPALI
Where MW is a molecular weight.
RO is calculated as ðCBRIS þ CBPALIÞ=Bmax.
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